Cromatina / Epigenética
Los inhibidores de cromatina/epigenética son compuestos que modulan la estructura y función de la cromatina o interfieren con modificaciones epigenéticas, como la metilación del ADN y la modificación de histonas. Estos inhibidores son herramientas esenciales para estudiar la regulación de la expresión génica y el papel de la epigenética en enfermedades como el cáncer, los trastornos neurológicos y las anomalías del desarrollo. Al dirigirse a los procesos epigenéticos, estos inhibidores pueden alterar los patrones de expresión génica y ofrecer nuevas vías terapéuticas. En CymitQuimica, ofrecemos una amplia selección de inhibidores de cromatina/epigenética de alta calidad para apoyar su investigación en biología molecular, genética y epigenética.
Subcategorías de "Cromatina / Epigenética"
Se han encontrado 2235 productos de "Cromatina / Epigenética"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
HIF1-IN-3
CAS:<p>HIF1-IN-3 (Benzenepropanamide, N-[(8-hydroxy-7-quinolinyl)(4-methoxyphenyl)methyl]-) is an effective inhibitor of HIF-1 (EC50 = 0.9 μM) and can be used in</p>Fórmula:C26H24N2O3Pureza:99.59%Forma y color:SolidPeso molecular:412.48Tyrosine Kinase Inhibitor Library
<p>A unique collection of 1016 tyrosine kinase inhibitors for high throughput screening and high content screening for drug discovery in tyrosine kinase related</p>Forma y color:Odour SolidPROTAC BRD4 Degrader-19
CAS:<p>PROTAC BRD4 Degrader-19 (compound 176) is a proteolysis-targeting chimera (PROTAC) designed to specifically degrade the BRD4 protein, offering potential utility</p>Fórmula:C44H38N8O5S2Forma y color:SolidPeso molecular:822.95GSK8573
CAS:<p>GSK8573 is an inactive control compound for GSK2801. GSK8573 has binding activity to BRD9 (Kd of 1.04 μM).</p>Fórmula:C20H21NO3Pureza:99.81%Forma y color:SolidPeso molecular:323.39PROTAC BET Degrader-1
CAS:<p>PROTAC BET Degrader-1 is a potent degrader of BET based on PROTAC.</p>Fórmula:C44H45N11O9Pureza:98%Forma y color:SolidPeso molecular:871.9MNK/PIM-IN-1
CAS:<p>MNK/PIM-IN-1 is a novel dual inhibitor targeting both MNK and PIM pathways, characterized by its favorable pharmacokinetic profile.</p>Fórmula:C27H27FN6O2Forma y color:SolidPeso molecular:486.551MNN-02-155
CAS:<p>MNN-02-155 is a bivalent molecular glue that can simultaneously interact with both p300/CBP and BCL6. It effectively induces the activation of BCL6-targeted reporter genes and promotes cell death. This compound is used in the research of diffuse large B-cell lymphoma (DLBCL).</p>Fórmula:C56H68ClF2N15O7Forma y color:SolidPeso molecular:1136.69PROTAC SMARCA2/4-degrader-25
<p>PROTAC SMARCA2/4-degrader-25 is a PROTAC that targets SMARCA2/4. It consists of the E3 ligase ligand (2S,4R)-4-Hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide, a PROTAC Linker (S)-2-Amino-3,3-dimethylbutanoic acid, and the target protein ligand SMARCA2/4-ligand-3. The conjugate of the E3 ubiquitin ligase ligand and Linker is (S,R,S)-AHPC.</p>Fórmula:C44H50N10O9S2Forma y color:SolidPeso molecular:927.06CDD-1102 HCl
<p>CDD-1102 HCl is a novel BRDT-BD4 / BRD2-BD1302 selective inhibitor that shows non-hormonal contraceptive potential in ex vivo experiments.</p>Fórmula:C32H31ClN6O3Pureza:98.30%Forma y color:SoildPeso molecular:583.08SIRT5 inhibitor 9
CAS:<p>SIRT5 inhibitor 9 (compound 14) is a moderately selective and substrate-competitive SIRT5 inhibitor with IC50=4.07 μM and has potential anticancer effects.</p>Fórmula:C24H29ClN8O4SPureza:98.68%Forma y color:SolidPeso molecular:561.06MZP-54
CAS:<p>MZP-54 is a selective degrader of BRD3/4 based on PROTAC technology(Kd of 4 nM for Brd4BD2)</p>Fórmula:C55H66ClN7O9SPureza:98%Forma y color:SolidPeso molecular:1036.67JAK-STAT Compound Library
<p>A unique collection of 252 JAK/STAT signaling targeted compounds for high throughput and high content screening;</p>Forma y color:Odour SolidUNC10142
<p>UNC10142 (Compound 44) is a small-molecule antagonist of CHD1, with a binding IC50 value of 1.7 μM. It induces a dose-dependent reduction in the viability of PTEN-deficient prostate cancer cells.</p>Fórmula:C33H52N6O3Forma y color:SolidPeso molecular:580.8HDAC1-IN-9
<p>HDAC1-IN-9 (13c) is an HDAC1 inhibitor. It inhibits the HDAC1 enzyme with an IC50 value of 1.07 µM. This compound exhibits the strongest antiproliferative activity against HT-29 (human colon adenocarcinoma cells), with an IC50 of 1.78 μM. In HCT-116 (human colon cancer cells), HDAC1-IN-9 significantly induces apoptosis. Additionally, HDAC1-IN-9 possesses antiangiogenic properties, reducing the expression levels of VEGFR-2 and phosphorylated VEGFR-2 (pVEGFR-2) by approximately 80%.</p>Fórmula:C17H17N3O3Forma y color:SolidPeso molecular:311.34PI3Kα/HDAC6-IN-1
<p>PI3Kα/HDAC6-IN-1 (compound 21j) is a dual inhibitor of PI3Kα and HDAC6, exhibiting IC50 values of 2.9 nM and 26 nM, respectively.</p>Fórmula:C27H30F3N7O6S2Pureza:98%Forma y color:SolidPeso molecular:669.7DNMT1/HDAC-IN-1
<p>DNMT1/HDAC-IN-1 (compound (R)-23a), a potent dual inhibitor targeting both DNMT1 and HDAC, exhibits impressive inhibitory effects specifically on HDAC1 (HDAC1:IC50=0.05 μM), a major HDAC isoform that interacts with DNMT1 across multiple protein complexes involved in the transcriptional silencing of TSGs. This compound has been shown to remodel the tumor immune microenvironment and induce tumor regression, effectively reversing cancer-specific epigenetic abnormalities.</p>Forma y color:Odour SolidPROTAC BRD4 Degrader-27
CAS:<p>PROTAC BRD4 Degrader-27 is a selective PROTAC targeting BRD4, distinguished from BRD2/BRD3. This compound is composed of the E3 ubiquitinase ligand Thalidomide-4-OH, the PROTAC Linker γ-Aminobutyric acid, and the PROTAC target protein ligand PROTAC BRD4 ligand-3. The active control for this target protein ligand is Mivebresib, while the conjugate of the E3 ubiquitin ligase ligand and Linker is identified as Pomalidomide 4'-alkylC3-acid.</p>Fórmula:C37H30F2N6O7Forma y color:SolidPeso molecular:708.67PRMT5-IN-12
CAS:<p>PRMT5-IN-12 shows remarkable inhibitory activity on PRMT5 .</p>Fórmula:C32H40N4O4Forma y color:SolidPeso molecular:544.696FDA-Approved Kinase Inhibitor Library
<p>A unique collection of 263 kinase inhibitors/regulators for specific targeting of kinases, ready for high-throughput screening and high-content screening.</p>Forma y color:LiquidHIV-1 protease-IN-10
<p>HIV-1 protease-IN-10 (Compound 2), exhibiting HIV-1 latency reversing activity (IC50: 0.22 μM), selectively binds to the PKCδ C1b domain (IC50: 0.69 μM) and</p>Fórmula:C23H40O5Pureza:98%Forma y color:SolidPeso molecular:396.56
